fluorouracil has been researched along with Weight Reduction in 60 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with no weight loss and/or preserved PS and with a limited disease extent appeared to obtain the greatest benefit from our irinotecan/5-FU/LV regimen, with acceptable toxicity." | 9.11 | Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 7.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 7.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| " The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis." | 7.81 | Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. ( Cardoso, VN; Carneiro, CM; Faria, AM; Ferreira, AV; Generoso, Sde V; Maioli, TU; Paiva, NC; Rodrigues, NM; Trindade, LM, 2015) |
| " In the present study, we investigated the role of NOX1 in the pathogenesis of intestinal mucositis induced by the cancer chemotherapeutic agent 5-fluorouracil (5-FU) in mice." | 7.78 | Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Amagase, K; Iimori, M; Iwata, K; Kato, S; Kitahara, Y; Matsuno, K; Takeuchi, K; Utsumi, D; Yabe-Nishimura, C; Yamanaka, N; Yasuda, M, 2012) |
| "PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models." | 7.74 | Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 7.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| "Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used." | 5.69 | The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023) |
| "The ADEBAR trial compares a sequential chemotherapy consisting of epirubicin/cyclophosphamide followed by docetaxel to an epirubicin/5-fluorouracil/cyclophosphamide regimen in patients with lymph node-positive early breast cancer." | 5.27 | Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. ( Beckmann, MW; de Gregorio, N; Fasching, PA; Fehm, T; Friedl, TWP; Harbeck, N; Jäger, B; Janni, W; Jückstock, J; Mahner, S; Mohrmann, S; Mutschler, NS; Rack, B; Salmen, J; Schochter, F; Scholz, C; Weissenbacher, T; Widschwendter, P; Ziegler, C; Zwingers, T, 2018) |
| "Patients with no weight loss and/or preserved PS and with a limited disease extent appeared to obtain the greatest benefit from our irinotecan/5-FU/LV regimen, with acceptable toxicity." | 5.11 | Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 3.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 3.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| " The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis." | 3.81 | Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. ( Cardoso, VN; Carneiro, CM; Faria, AM; Ferreira, AV; Generoso, Sde V; Maioli, TU; Paiva, NC; Rodrigues, NM; Trindade, LM, 2015) |
| " boulardii was not able to prevent the effects of experimental mucositis induced by 5- Fluorouracil." | 3.80 | Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. ( Cardoso, VN; Carneiro, CM; de Melo Silva, B; de Vasconcelos Generoso, S; Dias, MN; Dos Santos Martins, F; Fernandes, SO; Maioli, TU; Paiva, NC, 2014) |
| " In the present study, we investigated the role of NOX1 in the pathogenesis of intestinal mucositis induced by the cancer chemotherapeutic agent 5-fluorouracil (5-FU) in mice." | 3.78 | Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Amagase, K; Iimori, M; Iwata, K; Kato, S; Kitahara, Y; Matsuno, K; Takeuchi, K; Utsumi, D; Yabe-Nishimura, C; Yamanaka, N; Yasuda, M, 2012) |
| "PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models." | 3.74 | Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 3.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| "The scheduling of antifolate antitumor agents, including the new multitargeted autofolate LY231514 (MTA), with 5-fluorouracil was explored in the human MX-1 breast carcinoma and human H460 and Calu-6 non-small cell lung carcinoma xenografts to assess antitumor activity and toxicity (body weight loss)." | 3.70 | Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. ( Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA, 2000) |
| " Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival." | 3.69 | Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. ( Brien, JP; Bruskin, AM; Haley, JD; Muska, AD; Rose, A; Sonis, ST; Van Vugt, AG, 1997) |
| "Juzen-taiho-to (JTT; [Shi-quan-da-bu-tang], a Japanese modified Chinese herbal prescription) in combination with an anticancer drug UFT (5-fluorouracil derivative) prevented the body weight loss and the induction of the colonic cancer in rats treated with a chemical carcinogen 1,2-dimethylhydrazine (DMH), and suppressed markedly the activity of thymidylate synthetase (TS) involved in the de novo pathway of pyrimidine synthesis in colonic cancer induced by DMH." | 3.68 | Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. ( Kasahara, N; Kato, T; Kawasaki, T; Kudo, H; Kuwa, K; Nakayama, T; Okamoto, R; Sakamoto, S; Suzuki, S, 1991) |
| "Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies." | 3.11 | Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022) |
| "Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients." | 2.77 | Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012) |
| "5-Fluorouracil 225 mg/m2 was delivered as a continuous infusion on days 1 through 38." | 2.71 | Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. ( Bader, SB; Louie, J; Molendyk, J; Phillips, M; Regan, J; Ross, HJ; Ruzich, J; Seligman, M; Seung, SK; Skokan, L; Smith, JW; Soo, E, 2004) |
| "There was a higher risk of grade≥3 infection for weight loss at diagnosis (P=0." | 1.51 | [Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. ( Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N, 2019) |
| "The population pharmacokinetic model consisting of a two-compartment model with Michaelis-Menten elimination kinetics successfully characterized the individual and population predictions of the plasma concentration of 5-FU and provided credible parameter estimates." | 1.46 | Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats. ( Ito, Y; Kobuchi, S; Sakaeda, T, 2017) |
| "3%); alteration and complete recovery (31%) or sustained deterioration (45%), possibly due to inadequate chronotherapy dosing and/or timing." | 1.40 | The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. ( Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA, 2014) |
| "Patients with stage IVA esophageal cancer treated with chemoradiotherapy between April 2003 and March 2009 were evaluated." | 1.39 | Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy. ( Anbai, A; Hashimoto, M; Jin, M; Koga, M; Motoyama, S; Shibata, H, 2013) |
| "Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy." | 1.39 | Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013) |
| "5-fluorouracil (5-FU) is a common cytotoxic agent used to treat solid tumors." | 1.37 | CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. ( Cheng, Z; Di, J; Du, Y; Han, X; Jin, Z; Pan, Y; Wang, Y; Wang, Z; Wu, Z; Zhang, H; Zhang, P; Zheng, Q, 2011) |
| "All of the patients had squamous cell carcinoma." | 1.37 | Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. ( Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM, 2011) |
| "CRP was associated with disease progression and factors reflecting nutritional depletion such as serum albumin, lymphocyte count and body weight loss ratio." | 1.35 | Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. ( Inoue, Y; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Tanaka, K; Toiyama, Y; Yokoe, T, 2008) |
| " However, it was repeatedly shown that the sequence of 5-FU followed by CDDP is more active and less toxic in tumor-bearing animals." | 1.33 | Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. ( Fujimoto, S, 2006) |
| "Isoliquiritigenin is a chalcone isolated from licorice and shallots." | 1.31 | Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. ( Baba, M; Endo, H; Hamamoto, T; Joichi, Y; Kaneko, S; Morita, T; Nishino, H; Okada, Y; Okuyama, T; Tokue, A; Yamazaki, S, 2002) |
| " injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg." | 1.28 | Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.67) | 18.7374 |
| 1990's | 15 (25.00) | 18.2507 |
| 2000's | 13 (21.67) | 29.6817 |
| 2010's | 29 (48.33) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, S | 2 |
| Motoori, M | 2 |
| Yamasaki, M | 2 |
| Shiraishi, O | 2 |
| Miyata, H | 2 |
| Hirao, M | 2 |
| Takeno, A | 2 |
| Sugimura, K | 2 |
| Makino, T | 2 |
| Tanaka, K | 3 |
| Hamakawa, T | 2 |
| Yamashita, K | 2 |
| Kimura, Y | 2 |
| Fujitani, K | 2 |
| Yasuda, T | 2 |
| Yano, M | 2 |
| Doki, Y | 2 |
| Liu, L | 1 |
| Erickson, NT | 1 |
| Ricard, I | 1 |
| von Weikersthal, LF | 1 |
| Lerch, MM | 1 |
| Decker, T | 1 |
| Kiani, A | 1 |
| Kaiser, F | 1 |
| Heintges, T | 1 |
| Kahl, C | 1 |
| Kullmann, F | 1 |
| Scheithauer, W | 1 |
| Link, H | 1 |
| Höffkes, HG | 1 |
| Moehler, M | 1 |
| Gesenhues, AB | 1 |
| Theurich, S | 1 |
| Michl, M | 1 |
| Modest, DP | 1 |
| Algül, H | 1 |
| Stintzing, S | 1 |
| Heinemann, V | 1 |
| Holch, JW | 1 |
| Hamouda, N | 1 |
| Sano, T | 1 |
| Oikawa, Y | 1 |
| Ozaki, T | 1 |
| Shimakawa, M | 1 |
| Matsumoto, K | 1 |
| Amagase, K | 2 |
| Higuchi, K | 1 |
| Kato, S | 2 |
| Liu, Z | 1 |
| Xie, W | 1 |
| Li, M | 1 |
| Teng, N | 1 |
| Liang, X | 1 |
| Zhang, Z | 1 |
| Yang, Z | 1 |
| Wang, X | 2 |
| Yu, FJ | 1 |
| Shih, HY | 1 |
| Wu, CY | 1 |
| Chuang, YS | 1 |
| Lee, JY | 1 |
| Li, HP | 1 |
| Fang, PT | 1 |
| Tsai, DL | 1 |
| Chou, SH | 1 |
| Wu, IC | 1 |
| Mutschler, NS | 1 |
| Scholz, C | 1 |
| Friedl, TWP | 1 |
| Zwingers, T | 1 |
| Fasching, PA | 1 |
| Beckmann, MW | 1 |
| Fehm, T | 1 |
| Mohrmann, S | 1 |
| Salmen, J | 1 |
| Ziegler, C | 1 |
| Jäger, B | 1 |
| Widschwendter, P | 1 |
| de Gregorio, N | 1 |
| Schochter, F | 1 |
| Mahner, S | 1 |
| Harbeck, N | 1 |
| Weissenbacher, T | 1 |
| Jückstock, J | 1 |
| Janni, W | 1 |
| Rack, B | 1 |
| Kao, CT | 1 |
| Aziz, M | 1 |
| Kasi, A | 1 |
| Bernadach, M | 1 |
| Lapeyre, M | 1 |
| Dillies, AF | 1 |
| Miroir, J | 1 |
| Moreau, J | 1 |
| Kwiatkowski, F | 1 |
| Pham-Dang, N | 1 |
| Saroul, N | 1 |
| Durando, X | 1 |
| Biau, J | 1 |
| Neely, D | 1 |
| Ong, J | 1 |
| Patterson, J | 1 |
| Kirkpatrick, D | 1 |
| Skelly, R | 1 |
| Innominato, PF | 2 |
| Giacchetti, S | 1 |
| Moreau, T | 2 |
| Bjarnason, GA | 1 |
| Smaaland, R | 1 |
| Focan, C | 1 |
| Garufi, C | 1 |
| Iacobelli, S | 1 |
| Tampellini, M | 1 |
| Tumolo, S | 1 |
| Carvalho, C | 1 |
| Karaboué, A | 2 |
| Poncet, A | 1 |
| Spiegel, D | 1 |
| Lévi, F | 2 |
| Olson, R | 1 |
| Karam, I | 1 |
| Wilson, G | 1 |
| Bowman, A | 1 |
| Lee, C | 1 |
| Wong, F | 1 |
| Yao, Q | 1 |
| Ye, X | 1 |
| Wang, L | 1 |
| Gu, J | 1 |
| Fu, T | 1 |
| Wang, Y | 3 |
| Lai, Y | 1 |
| Jin, H | 1 |
| Guo, Y | 1 |
| Ortiz-Tudela, E | 1 |
| Iurisci, I | 1 |
| Beau, J | 1 |
| Rol, MA | 1 |
| Madrid, JA | 1 |
| Maioli, TU | 2 |
| de Melo Silva, B | 1 |
| Dias, MN | 1 |
| Paiva, NC | 2 |
| Cardoso, VN | 2 |
| Fernandes, SO | 1 |
| Carneiro, CM | 2 |
| Dos Santos Martins, F | 1 |
| de Vasconcelos Generoso, S | 1 |
| Rivera, F | 1 |
| Massutí, B | 1 |
| Salcedo, M | 1 |
| Sastre, J | 1 |
| Martínez Galán, J | 1 |
| Valladares-Ayerbes, M | 1 |
| Serrano, R | 1 |
| García de Paredes, ML | 1 |
| Manzano, JL | 1 |
| Galán, M | 1 |
| Alsina, M | 1 |
| Yuste Izquierdo, AL | 1 |
| López, C | 1 |
| Díaz-Rubio, E | 1 |
| Conde, V | 1 |
| Reboredo, M | 1 |
| Cano, MT | 1 |
| Pachón, V | 1 |
| Aranda, E | 1 |
| Generoso, Sde V | 1 |
| Rodrigues, NM | 1 |
| Trindade, LM | 1 |
| Ferreira, AV | 1 |
| Faria, AM | 1 |
| Kobuchi, S | 1 |
| Ito, Y | 1 |
| Sakaeda, T | 1 |
| Koike, Y | 1 |
| Miki, C | 1 |
| Okugawa, Y | 1 |
| Yokoe, T | 2 |
| Toiyama, Y | 1 |
| Inoue, Y | 1 |
| Kusunoki, M | 1 |
| Dintinjana, RD | 1 |
| Guina, T | 1 |
| Krznarić, Z | 1 |
| Radić, M | 1 |
| Dintinjana, M | 1 |
| Ersoy, E | 1 |
| Akbulut, H | 1 |
| Moray, G | 1 |
| Buiret, G | 1 |
| Combe, C | 1 |
| Favrel, V | 1 |
| Pommier, P | 1 |
| Martin, L | 1 |
| Ecochard, R | 1 |
| Fayette, J | 1 |
| Tartas, S | 1 |
| Ramade, A | 1 |
| Céruse, P | 1 |
| Janelsins, MC | 1 |
| Roscoe, JA | 1 |
| Berg, MJ | 1 |
| Thompson, BD | 1 |
| Gallagher, MJ | 1 |
| Morrow, GR | 1 |
| Heckler, CE | 1 |
| Jean-Pierre, P | 1 |
| Opanashuk, LA | 1 |
| Gross, RA | 1 |
| Clavel, S | 1 |
| Fortin, B | 1 |
| Després, P | 1 |
| Donath, D | 1 |
| Soulières, D | 1 |
| Khaouam, N | 1 |
| Charpentier, D | 1 |
| Bélair, M | 1 |
| Guertin, L | 1 |
| Nguyen-Tan, PF | 1 |
| Park, JW | 1 |
| Kim, JH | 1 |
| Choi, EK | 1 |
| Lee, SW | 1 |
| Yoon, SM | 1 |
| Song, SY | 1 |
| Lee, YS | 1 |
| Kim, SB | 1 |
| Park, SI | 1 |
| Ahn, SD | 1 |
| Prestwich, RJ | 1 |
| Öksüz, DÇ | 1 |
| Dyker, K | 1 |
| Coyle, C | 1 |
| Şen, M | 1 |
| Han, X | 1 |
| Wu, Z | 1 |
| Di, J | 1 |
| Pan, Y | 1 |
| Zhang, H | 1 |
| Du, Y | 1 |
| Cheng, Z | 1 |
| Jin, Z | 1 |
| Wang, Z | 1 |
| Zheng, Q | 1 |
| Zhang, P | 1 |
| Yen, SH | 1 |
| Wang, LW | 1 |
| Lin, YH | 1 |
| Jen, YM | 1 |
| Chung, YL | 1 |
| Chou, TC | 1 |
| Dong, H | 1 |
| Zhang, X | 1 |
| Lei, X | 1 |
| Hartung, J | 1 |
| Zhang, Y | 1 |
| Lee, JH | 1 |
| Wilson, RM | 1 |
| Danishefsky, SJ | 1 |
| Ramachandran, S | 1 |
| Mandal, M | 1 |
| Bonatto, SJ | 1 |
| Oliveira, HH | 1 |
| Nunes, EA | 1 |
| Pequito, D | 1 |
| Iagher, F | 1 |
| Coelho, I | 1 |
| Naliwaiko, K | 1 |
| Kryczyk, M | 1 |
| Brito, GA | 1 |
| Repka, J | 1 |
| Sabóia, LV | 1 |
| Fukujima, G | 1 |
| Calder, PC | 1 |
| Fernandes, LC | 1 |
| Yasuda, M | 1 |
| Yamanaka, N | 1 |
| Iimori, M | 1 |
| Utsumi, D | 1 |
| Kitahara, Y | 1 |
| Iwata, K | 1 |
| Matsuno, K | 1 |
| Yabe-Nishimura, C | 1 |
| Takeuchi, K | 1 |
| Tomita, M | 1 |
| Matsuyama, H | 1 |
| Yamazaki, K | 1 |
| Sato, K | 1 |
| Takahashi, S | 1 |
| Peerawong, T | 1 |
| Phungrassami, T | 1 |
| Pruegsanusak, K | 1 |
| Sangthong, R | 1 |
| Anbai, A | 1 |
| Koga, M | 1 |
| Motoyama, S | 1 |
| Jin, M | 1 |
| Shibata, H | 1 |
| Hashimoto, M | 1 |
| Tebbutt, NC | 2 |
| Norman, A | 2 |
| Cunningham, D | 3 |
| Iveson, T | 1 |
| Seymour, M | 1 |
| Hickish, T | 1 |
| Harper, P | 1 |
| Maisey, N | 1 |
| Mochlinski, K | 1 |
| Prior, Y | 1 |
| Hill, M | 2 |
| Kelleher, M | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| Seung, SK | 1 |
| Smith, JW | 1 |
| Molendyk, J | 1 |
| Bader, SB | 1 |
| Phillips, M | 1 |
| Regan, J | 1 |
| Louie, J | 1 |
| Soo, E | 1 |
| Seligman, M | 1 |
| Ruzich, J | 1 |
| Skokan, L | 1 |
| Ross, HJ | 1 |
| Lin, A | 1 |
| Jabbari, S | 1 |
| Worden, FP | 1 |
| Bradford, CR | 1 |
| Chepeha, DB | 1 |
| Teknos, TN | 1 |
| Liao, JJ | 1 |
| Nyquist, GG | 1 |
| Tsien, C | 1 |
| Schipper, MJ | 1 |
| Urba, S | 1 |
| Wolf, GT | 1 |
| Eisbruch, A | 1 |
| Comella, P | 1 |
| Massidda, B | 1 |
| Filippelli, G | 1 |
| Natale, D | 1 |
| Farris, A | 1 |
| Buzzi, F | 1 |
| Tafuto, S | 1 |
| Maiorino, L | 1 |
| Palmeri, S | 1 |
| De Lucia, L | 1 |
| Mancarella, S | 1 |
| Leo, S | 1 |
| Roselli, M | 1 |
| Lorusso, V | 1 |
| De Cataldis, G | 1 |
| Fujimoto-Ouchi, K | 1 |
| Onuma, E | 1 |
| Shirane, M | 1 |
| Mori, K | 1 |
| Tanaka, Y | 1 |
| Fujimoto, S | 1 |
| Le Bricon, T | 1 |
| Gugins, S | 1 |
| Cynober, L | 1 |
| Baracos, VE | 1 |
| Sonis, S | 1 |
| Muska, A | 1 |
| O'Brien, J | 1 |
| Van Vugt, A | 1 |
| Langer-Safer, P | 1 |
| Keith, J | 2 |
| Galandiuk, S | 1 |
| Wrightson, W | 1 |
| Marr, L | 1 |
| Myers, S | 1 |
| LaRocca, RV | 1 |
| Van Laar, JA | 3 |
| Rustum, YM | 2 |
| Van der Wilt, CL | 3 |
| Smid, K | 2 |
| Kuiper, CM | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 3 |
| Prott, FJ | 1 |
| Schönekaes, K | 1 |
| Preusser, P | 1 |
| Ostkamp, K | 1 |
| Wagner, W | 1 |
| Micke, O | 1 |
| Pötter, R | 1 |
| Sulkowski, U | 1 |
| Rübe, C | 1 |
| Berns, T | 1 |
| Willich, N | 1 |
| Sonis, ST | 2 |
| Van Vugt, AG | 2 |
| Brien, JP | 1 |
| Muska, AD | 1 |
| Bruskin, AM | 1 |
| Rose, A | 1 |
| Haley, JD | 1 |
| McDonald, J | 1 |
| Dotoli, E | 1 |
| Schwertschlag, U | 1 |
| Szklut, P | 1 |
| Cao, S | 1 |
| Troutt, AB | 1 |
| Andreyev, HJ | 1 |
| Norman, AR | 1 |
| Oates, J | 1 |
| Arikan, AY | 1 |
| Senel, FM | 1 |
| Akman, RY | 1 |
| Can, C | 1 |
| Teicher, BA | 1 |
| Chen, V | 1 |
| Shih, C | 1 |
| Menon, K | 1 |
| Forler, PA | 1 |
| Phares, VG | 1 |
| Amsrud, T | 1 |
| Jian, JJ | 1 |
| Cheng, SH | 1 |
| Tsai, SY | 1 |
| Yen, KC | 1 |
| Chu, NM | 1 |
| Chan, KY | 1 |
| Tan, TD | 1 |
| Cheng, JC | 1 |
| Lin, YC | 1 |
| Leu, SY | 1 |
| Hsieh, CI | 1 |
| Tsou, MH | 1 |
| Lin, CY | 1 |
| Huang, AT | 1 |
| Yamazaki, S | 1 |
| Morita, T | 1 |
| Endo, H | 1 |
| Hamamoto, T | 1 |
| Baba, M | 1 |
| Joichi, Y | 1 |
| Kaneko, S | 1 |
| Okada, Y | 1 |
| Okuyama, T | 1 |
| Nishino, H | 1 |
| Tokue, A | 1 |
| Gyergyay, F | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Iino, Y | 1 |
| Yoshida, M | 1 |
| Sugamata, N | 1 |
| Maemura, M | 1 |
| Ohwada, S | 1 |
| Ishikita, T | 1 |
| Horiuchi, R | 1 |
| Morishita, Y | 1 |
| de Roy van Zuidewijn, DB | 1 |
| Hendriks, T | 1 |
| Wobbes, T | 1 |
| de Boer, HH | 1 |
| Sakamoto, S | 1 |
| Kudo, H | 1 |
| Kuwa, K | 1 |
| Suzuki, S | 1 |
| Kato, T | 1 |
| Kawasaki, T | 1 |
| Nakayama, T | 1 |
| Kasahara, N | 1 |
| Okamoto, R | 1 |
| Allum, WH | 1 |
| Hallissey, MT | 1 |
| Kelly, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
| Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.[NCT00733616] | Phase 2 | 44 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| [NCT02603159] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.[NCT02456506] | 142 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluorouracil and Weight Reduction
| Article | Year |
|---|---|
Small intestinal adenocarcinoma: rarely considered, often missed?
Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do | 2013 |
Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
Topics: Adenocarcinoma; Aged; Antidotes; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease | 1997 |
11 trials available for fluorouracil and Weight Reduction
| Article | Year |
|---|---|
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2022 |
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuv | 2018 |
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2015 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Fish oil supplementation improves neutrophil function during cancer chemotherapy.
Topics: Antineoplastic Agents; Brazil; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fe | 2012 |
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2002 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free | 2004 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2005 |
Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy | 1989 |
47 other studies available for fluorouracil and Weight Reduction
| Article | Year |
|---|---|
Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cyto | 2017 |
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect | 2017 |
Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutiti | 2018 |
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2018 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2019 |
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2013 |
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2013 |
Protective effect of curcumin on chemotherapy-induced intestinal dysfunction.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Biomarkers; | 2013 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2014 |
Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice.
Topics: Animals; Antimetabolites, Antineoplastic; Feeding Behavior; Fluorouracil; Intestinal Mucosa; Mice; M | 2014 |
Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice.
Topics: Animals; Apoptosis; Dietary Supplements; Escherichia coli; Fatty Acids, Omega-3; Fluorouracil; Ileum | 2015 |
Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
Topics: Administration, Intravenous; Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Dose-Respon | 2017 |
Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Prote | 2008 |
Effects of nutritional support in patients with colorectal cancer during chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Mass Index; Camptothecin; Color | 2008 |
Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses.
Topics: Anastomosis, Surgical; Animals; Antineoplastic Agents; Colonic Neoplasms; Disease Models, Animal; Fe | 2009 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bromodeoxyuridine; Cell Proliferation; Cyclopho | 2010 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Chemokine CXCL9; Diarrhea; | 2011 |
Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol.
Topics: Animals; Biological Products; Cell Death; Cytoprotection; Enediynes; Fatty Alcohols; Female; Fluorou | 2011 |
Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Pro | 2011 |
Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase | 2012 |
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Comparison of treatment compliance and nutritional outcomes among patients with nasopharyngeal carcinoma with and without percutaneous endoscopic gastrostomy during chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci | 2012 |
Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemoradiotherapy; | 2013 |
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin | 2005 |
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercal | 2007 |
Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin | 2006 |
Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats.
Topics: Animals; Antineoplastic Agents; Cachexia; Cisplatin; Cyclophosphamide; DNA; Eating; Female; Fluorour | 1995 |
Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cricetinae; Dose-Response Relationship, Drug; | 1995 |
Suppository delivery of 5-fluorouracil in rectal cancer.
Topics: Administration, Rectal; Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liqu | 1996 |
Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
Topics: Adenocarcinoma; Animals; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1996 |
Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Division; Cricet | 1997 |
Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters.
Topics: Animals; Blood Cell Count; Bone Marrow Cells; Cricetinae; Fluorouracil; Interleukin-11; Male; Mesocr | 1997 |
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
Comparison of the effects of various anticancer agents on intestinal anastomosis after intraperitoneal administration.
Topics: Analysis of Variance; Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Antineoplasti | 1999 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, N | 2000 |
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2002 |
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Chalcone; Chalcones; Dose-Response Relationsh | 2002 |
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inb | 1992 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne | 1992 |
1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Divi | 1992 |
Intraperitoneal cytostatics impair healing of experimental intestinal anastomoses.
Topics: Anastomosis, Surgical; Animals; Bleomycin; Body Weight; Cisplatin; Colon; Fluorouracil; Hydroxyproli | 1991 |
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eva | 1991 |